ロード中...
The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report
BACKGROUND: Since tacrolimus ointment was approved by the U.S. Food and Drug Administration (FDA) as a promising treatment for atopic dermatitis, it has been approved in more than 30 additional countries, including numerous European Union member nations. Moreover, in the current clinical routine the...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2006
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1386691/ https://ncbi.nlm.nih.gov/pubmed/16405733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-6-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|